WO2004096148A3 - Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof - Google Patents
Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof Download PDFInfo
- Publication number
- WO2004096148A3 WO2004096148A3 PCT/US2004/013099 US2004013099W WO2004096148A3 WO 2004096148 A3 WO2004096148 A3 WO 2004096148A3 US 2004013099 W US2004013099 W US 2004013099W WO 2004096148 A3 WO2004096148 A3 WO 2004096148A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue protective
- assays
- compounds
- receptor complex
- complex
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004233985A AU2004233985A1 (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
BRPI0409678-9A BRPI0409678A (en) | 2003-04-25 | 2004-04-26 | methods for identifying a compound, for treating or preventing a disease or disorder in a human, for enhancing the function of excitable organs, tissues, or cells in a human, and for modulating the activity of a tissue-protecting cytokine receptor complex in a human human |
CA002523578A CA2523578A1 (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
JP2006513398A JP2006524827A (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
EP04760431A EP1622570A4 (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
MXPA05011134A MXPA05011134A (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof. |
US10/554,517 US20090136519A1 (en) | 2003-04-25 | 2004-04-26 | Tissue Protective Cytokine Receptor Complex, Assays for Identifying Tissue Protective Compounds and Uses Thereof |
NZ543192A NZ543192A (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
EA200501667A EA009745B1 (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
IS8075A IS8075A (en) | 2003-04-25 | 2005-10-14 | Tissue Receptor Cell Prototype, Tests to Identify Tissue Protective Compounds and Their Use |
US11/259,326 US20060216757A1 (en) | 2003-04-25 | 2005-10-25 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
NO20055525A NO20055525L (en) | 2003-04-25 | 2005-11-23 | Tissue Protective Cytokine Receptor Complex Assay for Identifying Tissue Protective Compounds and Uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46589103P | 2003-04-25 | 2003-04-25 | |
US60/465,891 | 2003-04-25 | ||
US10/676,694 | 2003-09-30 | ||
US10/676,694 US7718363B2 (en) | 2003-04-25 | 2003-09-30 | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/676,694 Continuation-In-Part US7718363B2 (en) | 2003-04-25 | 2003-09-30 | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/259,326 Continuation US20060216757A1 (en) | 2003-04-25 | 2005-10-25 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004096148A2 WO2004096148A2 (en) | 2004-11-11 |
WO2004096148A3 true WO2004096148A3 (en) | 2006-03-02 |
Family
ID=33303293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/013099 WO2004096148A2 (en) | 2003-04-25 | 2004-04-26 | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (2) | US7718363B2 (en) |
EP (1) | EP1622570A4 (en) |
JP (1) | JP2006524827A (en) |
KR (1) | KR20050121270A (en) |
AU (1) | AU2004233985A1 (en) |
BR (1) | BRPI0409678A (en) |
CA (1) | CA2523578A1 (en) |
EA (1) | EA009745B1 (en) |
IS (1) | IS8075A (en) |
MX (1) | MXPA05011134A (en) |
NO (1) | NO20055525L (en) |
NZ (1) | NZ543192A (en) |
WO (1) | WO2004096148A2 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
KR20040070254A (en) * | 2001-12-20 | 2004-08-06 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Antibodies that immunospecifically bind to TRAIL receptors |
CA2519092C (en) | 2003-03-14 | 2014-08-05 | Neose Technologies, Inc. | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US20060216757A1 (en) * | 2003-04-25 | 2006-09-28 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
ES2380093T3 (en) | 2003-05-09 | 2012-05-08 | Biogenerix Ag | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
US10191028B1 (en) * | 2003-06-06 | 2019-01-29 | Ionwerks | Inorganic nanoparticle matrices for sample analysis |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
ZA200603396B (en) * | 2003-09-29 | 2007-11-28 | Warren Pharmaceuticals Inc | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
CN101072789B (en) | 2004-01-08 | 2013-05-15 | 生物种属学股份公司 | O-linked glycosylation of peptides |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
JP5216580B2 (en) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | Glycopegylated factor IX |
SG2014007868A (en) | 2005-08-05 | 2014-05-29 | Araim Pharmaceuticals Inc | Tissue protective peptides and uses thereof |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
EP1760092A1 (en) * | 2005-08-26 | 2007-03-07 | Applied Research Systems ARS Holding N.V. | System for screening cells for high expression of a protein of interest |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
JP2009544327A (en) | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | Glycosylation of peptides with O-linked glycosylation sequences |
JP2010505874A (en) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | Purification method for polypeptide conjugates |
KR20150064246A (en) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | Methods of treatment using glycopegylated g―csf |
JP5876649B2 (en) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | Improved process for producing nucleotide sugars |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US8357501B2 (en) | 2007-11-29 | 2013-01-22 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (NEPOR) and methods of use |
PL2492355T3 (en) * | 2007-11-29 | 2015-09-30 | Molecular Health Gmbh | Tissue protective erythropoietin receptor (nepor) and methods of use |
SG10201604530SA (en) | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
CN103497246B (en) | 2008-02-27 | 2016-08-10 | 诺沃—诺迪斯克有限公司 | The Factor VlII molecule puted together |
WO2010083532A1 (en) * | 2009-01-19 | 2010-07-22 | The Research Foundaton Of State University Of New York | Fatty acid binding proteins as drug targets for modulation of endocannabinoids |
JP6087816B2 (en) * | 2010-07-19 | 2017-03-01 | オタゴ イノベーション リミテッド | Signal biomarker |
DK2880170T3 (en) | 2012-08-02 | 2016-10-24 | Hoffmann La Roche | PROCEDURE FOR PREPARING SOLUBLE FcR AS Fc FUSION WITH INERT IMMUNOGLOBULIN Fc REGION AND APPLICATIONS THEREOF |
JP6479789B2 (en) * | 2013-07-17 | 2019-03-13 | アライム ファーマシューティカルズ,インコーポレーテッド | Tissue protective peptides and peptide analogs to prevent and treat diseases and disorders associated with tissue damage |
US10544472B2 (en) * | 2014-01-18 | 2020-01-28 | Attagene, Inc. | Multiplexing transcription factor reporter protein assay process and system |
RU2612913C2 (en) * | 2015-05-12 | 2017-03-13 | Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" | Method of increasing life span of molluscs abra segmentum under conditions of hypoxia for period from 4 to 14 days |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US20240053325A1 (en) * | 2020-12-11 | 2024-02-15 | President And Fellows Of Harvard College | Novel screening platform to identify immune modulatory agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278065A (en) * | 1989-02-03 | 1994-01-11 | Genetics Institute, Inc. | Recombinant DNA endoding an erythropoietin receptor |
US5997865A (en) * | 1994-04-04 | 1999-12-07 | Bennett; Brian D. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5292654A (en) * | 1990-12-13 | 1994-03-08 | Whitehead Institute For Biomedical Research | Mutant EPO receptor and uses therefor |
DE4228839A1 (en) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Methods for the detection and determination of mediators |
JPH09501833A (en) | 1993-08-16 | 1997-02-25 | リー,ジョン・ワイ | Human erythropoietin receptor fragment and antibody thereto |
US5763198A (en) * | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
ES2249774T3 (en) * | 1994-12-22 | 2006-04-01 | Novartis Ag | PROTEINS SERINA / TRONINA NUCLEAR KINASES. |
AUPN780096A0 (en) | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
EP0929691B1 (en) * | 1996-09-24 | 2004-12-15 | Cadus Pharmaceutical Corporation | Methods and compositions for identifying receptor effectors |
DE19857609A1 (en) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
TR200402194T2 (en) | 1999-04-13 | 2004-10-21 | The Kenneth S. Warren Institute, Inc. | Regulation of excitable tissue function via peripherally administered erythropoietin |
US7309687B1 (en) | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
US7345019B1 (en) * | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
ES2593002T3 (en) | 2000-06-26 | 2016-12-05 | Zymogenetics, Inc. | ZCYTOR17 cytokine receptor |
US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
PA8536201A1 (en) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
BR0312395A (en) | 2002-07-01 | 2007-06-19 | Kenneth S Warren Inst Inc | recombinant mutein protective tissue cytokine, mammalian cell responsive recombinant tissue protective cytokine, isolated nucleic acid molecule, vector, expression vector, genetically engineered cell, cell, pharmaceutical composition, method for protecting, maintaining or enhancing the viability of a cell, tissue or organ isolated from a mammalian body, use of a recombinant tissue protective cytokine, method for facilitating the transcytosis of a molecule through an endothelial cell barrier in a mammal, and composition for transporting a molecule through of transcytosis through an endothelial cell barrier |
CN101371920A (en) | 2002-09-09 | 2009-02-25 | 沃伦药品公司 | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
US20050176627A1 (en) * | 2002-09-09 | 2005-08-11 | Anthony Cerami | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
US20060216757A1 (en) * | 2003-04-25 | 2006-09-28 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
EA200501828A1 (en) | 2003-05-19 | 2006-08-25 | Дзе Кеннет С. Уоррен Инститьют, Инк. | TISSUE PROTECTOR CYTOKINES WITH ENLARGED THERAPEUTIC WINDOW FOR PROTECTION, RESTORATION AND STIMULATION OF REACTIVE CELLS, TISSUES AND BODIES |
BRPI0409650A (en) | 2003-09-09 | 2006-04-25 | Warren Pharmaceuticals Inc | methods for regulating hematocrit and human levels, artificial erythropoietin products, methods for preparing an erythropoietin product and for treating anemia in patients at risk of tissue damage, and, pharmaceutical composition |
ZA200603396B (en) | 2003-09-29 | 2007-11-28 | Warren Pharmaceuticals Inc | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
WO2005084364A2 (en) | 2004-03-03 | 2005-09-15 | The Kenneth S. Warren Institue, Inc. | Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
BRPI0412869A (en) | 2004-05-20 | 2006-10-03 | Kenneth S Warren Inst Inc | use of a tissue-protecting erythropoietin or cytokine, and method for protecting or maintaining the viability of a responsive mammalian cell, tissue or organ |
WO2006014466A2 (en) | 2004-07-02 | 2006-02-09 | The Kenneth S. Warren Institute, Inc. | Novel carbamylated epo and method for its production |
WO2006014349A2 (en) | 2004-07-02 | 2006-02-09 | The Kenneth S. Warren Institute, Inc. | Method of producing fully carbamylated erythropoietin |
EP1781697B1 (en) | 2004-07-07 | 2009-04-22 | H.Lundbeck A/S | Novel carbamylated epo and method for its production |
KR20090052355A (en) * | 2006-08-14 | 2009-05-25 | 시코르, 인크. | Highly pure pemetrexed diacid and processes for the preparation thereof |
US20080045409A1 (en) * | 2006-08-16 | 2008-02-21 | Buarque De Macedo Pedro M | Ceramic catalysts |
US8538421B2 (en) * | 2008-10-20 | 2013-09-17 | At&T Mobility Ii Llc | Management of network technology selection and display in multi-technology wireless environments |
US9030606B2 (en) * | 2013-03-14 | 2015-05-12 | Gopro, Inc. | Wireless camera housing illuminators |
US9290938B2 (en) * | 2014-04-09 | 2016-03-22 | Wickright, Inc. | Construction system for releasing moisture from a hip, valley or gable roof |
-
2003
- 2003-09-30 US US10/676,694 patent/US7718363B2/en not_active Expired - Fee Related
-
2004
- 2004-04-26 BR BRPI0409678-9A patent/BRPI0409678A/en not_active IP Right Cessation
- 2004-04-26 EP EP04760431A patent/EP1622570A4/en not_active Withdrawn
- 2004-04-26 NZ NZ543192A patent/NZ543192A/en unknown
- 2004-04-26 EA EA200501667A patent/EA009745B1/en not_active IP Right Cessation
- 2004-04-26 JP JP2006513398A patent/JP2006524827A/en active Pending
- 2004-04-26 CA CA002523578A patent/CA2523578A1/en not_active Abandoned
- 2004-04-26 MX MXPA05011134A patent/MXPA05011134A/en not_active Application Discontinuation
- 2004-04-26 KR KR1020057020323A patent/KR20050121270A/en not_active Application Discontinuation
- 2004-04-26 AU AU2004233985A patent/AU2004233985A1/en not_active Abandoned
- 2004-04-26 US US10/554,517 patent/US20090136519A1/en not_active Abandoned
- 2004-04-26 WO PCT/US2004/013099 patent/WO2004096148A2/en active Application Filing
-
2005
- 2005-10-14 IS IS8075A patent/IS8075A/en unknown
- 2005-11-23 NO NO20055525A patent/NO20055525L/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5278065A (en) * | 1989-02-03 | 1994-01-11 | Genetics Institute, Inc. | Recombinant DNA endoding an erythropoietin receptor |
US5997865A (en) * | 1994-04-04 | 1999-12-07 | Bennett; Brian D. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP1622570A4 * |
Also Published As
Publication number | Publication date |
---|---|
IS8075A (en) | 2005-10-14 |
CA2523578A1 (en) | 2004-11-11 |
US20090136519A1 (en) | 2009-05-28 |
EA200501667A1 (en) | 2006-06-30 |
MXPA05011134A (en) | 2006-05-25 |
KR20050121270A (en) | 2005-12-26 |
NO20055525D0 (en) | 2005-11-23 |
EP1622570A2 (en) | 2006-02-08 |
NZ543192A (en) | 2008-07-31 |
WO2004096148A2 (en) | 2004-11-11 |
JP2006524827A (en) | 2006-11-02 |
AU2004233985A1 (en) | 2004-11-11 |
BRPI0409678A (en) | 2006-05-02 |
NO20055525L (en) | 2006-01-16 |
US7718363B2 (en) | 2010-05-18 |
US20040214236A1 (en) | 2004-10-28 |
EA009745B1 (en) | 2008-04-28 |
EP1622570A4 (en) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004096148A3 (en) | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof | |
BRPI0415210A (en) | compounds and compositions as protein kinase inhibitors | |
BRPI0409173A (en) | compounds and compositions as protein kinase inhibitors | |
AU2005253776A8 (en) | Screening methods using c-Abl, Fyn and Syk in combination with tau protein | |
EP2275096A3 (en) | Neurogenesis via modulation of the muscarinic receptors | |
WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
HK1116349A1 (en) | Pyrrolopyrimidines useful as inhibitors of protein kinase | |
DE60327999D1 (en) | AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES | |
WO2007143098A3 (en) | Hepatocyte growth factor (hgf) binding proteins | |
WO2007076473A3 (en) | Substituted pyrimidinyloxy ureas useful as inhibitors of protein kinases | |
BRPI0511477A (en) | compounds and compositions as modulators of ppar | |
WO2007134077A3 (en) | 5 ht receptor mediated neurogenesis | |
WO2007143090A3 (en) | Hepatocyte growth factor (hgf) binding proteins | |
BRPI0613859A8 (en) | nitrocathecol derivatives, their use and preparation process, as well as pharmaceutical composition | |
IL177015B (en) | Isolated human rpe cells and use thereof for the treatment of degenerative disease of the retina | |
WO2007056163A3 (en) | Aminopyrimidines useful as kinase inhibitors | |
WO2007087068A3 (en) | Inhibitors of tyrosine kinases and uses thereof | |
WO1998019167A3 (en) | Cell stress regulated human mhc class i gene | |
WO2006091546A3 (en) | Use of amniotic fluid (af) in treating ocular disease and injury | |
WO2008097861A3 (en) | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS | |
MX2009006685A (en) | Dr6 antagonists and uses thereof in treating neurological disorders. | |
WO2007079400A3 (en) | Self-adhesive protective substrate | |
ATE435858T1 (en) | PRODRUGS OF PYRROLYLPYRIMIDINES ACTING AS ERK PROTEIN KINASE INHIBITORS | |
BR0316296A (en) | Lapacone compounds and their methods of use | |
BR0314053A (en) | Pyrazolopyridines and methods of obtaining and using them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/011134 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/08434 Country of ref document: ZA Ref document number: 200508434 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 171466 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 543192 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004233985 Country of ref document: AU Ref document number: 2006513398 Country of ref document: JP Ref document number: 2750/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2523578 Country of ref document: CA Ref document number: 11259326 Country of ref document: US Ref document number: 1020057020323 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2004233985 Country of ref document: AU Date of ref document: 20040426 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004233985 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05119097 Country of ref document: CO Ref document number: 200501667 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004760431 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048177059 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057020323 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004760431 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0409678 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 11259326 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10554517 Country of ref document: US |